While the remaining business is not busted, it does seem fragile, with the company facing headwinds in both multiple sclerosis and spinal muscular atrophy, according to Raymond James.
Raymond James’ Steven Seedhouse resumed coverage of Biogen with a Market Perform rating.
Biogen’s MS franchise is facing several risks, including new launches like Celgene Corporation (NASDAQ: CELG)'s ozanimod; Novartis AG (NYSE: NVS)'s Mayzent; Merck's Mavenclad; a pending IPR decision on Biogen's Tecfidera IP and pricing that's subject to intense political pressure in the U.S., Seedhouse said in a Tuesday note.
In the spinal muscular atrophy arena, the annual sales of Spinraza have already peaked, with market share remaining flat and the dosing mix shifting from loading to maintenance, the analyst said. The latter signifies a massive cut in the gross price, from $750,000 to $375,000 per year per patient, he said.
Spinraza sales will be further impacted by the launches of Zolgesma by Novartis and risdiplam by Roche Holding and PTC Therapeutics, Inc. (NASDAQ: PTCT), Seedhouse said.
Biogen seems to understand the challenges ahead “to retool the business outlook and growth prospects in a stepwise manner,” the analyst said.
Biogen shares were trading down 0.13 percent at $237.28 at the time of publication Wednesday.
The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead
6 Gene Therapy M&A Targets On The Radar
Latest Ratings for BIIB
|Mar 2019||Canaccord Genuity||Downgrades||Buy||Hold|
View More Analyst Ratings for BIIB
View the Latest Analyst Ratings
See more from Benzinga
- First Merchants Analyst Says Bank Has Improved Prospects After MBT Financial Acquisition
- Raymond James Bullish On Old Second Bancorp's Growth, Profitability
- JPMorgan Downgrades HB Fuller On Volume Headwinds Due To Global Economic Slowdown
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.